Search research articles
Contact Us
Filters
Showing results (31-40 of 78) with videos related to
Page
of 8
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 30, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy
Erica Stringer-Reasor, Yufeng Li, Jianqing Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 30, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy
Erica Stringer-Reasor, Yufeng Li, Jianqing Zhang, et al.
Breast Cancer Research : BCR
|
November 30, 2011
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation
Yen-Chao Wang, Gladys Morrison, Ryan Gillihan, et al.
Clinical Breast Cancer
|
December 25, 2014
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer
Mothaffar F Rimawi, Sabina B Aleixo, Ashley Alarcon Rozas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2021
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>-</sup> Breast Cancer
Mitch Dowsett, Lucy Kilburn, Mothaffar F Rimawi, et al.
Clinical Breast Cancer
|
November 13, 2017
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27
Polly Niravath, Bingshu Chen, Judy-Anne W Chapman, et al.
British Journal of Cancer
|
December 18, 2018
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
Agostina Nardone, Hazel Weir, Oona Delpuech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Mothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
The New England Journal of Medicine
|
October 29, 2025
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
Sara M Tolaney, Zefei Jiang, Qingyuan Zhang, et al.
Cancer Research
|
September 28, 2016
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes
Andriy Marusyk, Doris P Tabassum, Michalina Janiszewska, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 78) with videos related to
Sort By:
Page
of 8
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 30, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy
Erica Stringer-Reasor, Yufeng Li, Jianqing Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 30, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy
Erica Stringer-Reasor, Yufeng Li, Jianqing Zhang, et al.
Breast Cancer Research : BCR
|
November 30, 2011
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation
Yen-Chao Wang, Gladys Morrison, Ryan Gillihan, et al.
Clinical Breast Cancer
|
December 25, 2014
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer
Mothaffar F Rimawi, Sabina B Aleixo, Ashley Alarcon Rozas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2021
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>-</sup> Breast Cancer
Mitch Dowsett, Lucy Kilburn, Mothaffar F Rimawi, et al.
Clinical Breast Cancer
|
November 13, 2017
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27
Polly Niravath, Bingshu Chen, Judy-Anne W Chapman, et al.
British Journal of Cancer
|
December 18, 2018
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
Agostina Nardone, Hazel Weir, Oona Delpuech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Mothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
The New England Journal of Medicine
|
October 29, 2025
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
Sara M Tolaney, Zefei Jiang, Qingyuan Zhang, et al.
Cancer Research
|
September 28, 2016
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes
Andriy Marusyk, Doris P Tabassum, Michalina Janiszewska, et al.
Page
of 8